WebTafinlar: Dabrafenib belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the family of medications called protein kinase … WebApr 7, 2024 · Chest pain, sudden shortness of breath, trouble breathing, pain in your legs with or without swelling, swelling in your arms and legs, or a cool, pale arm or leg. These may be symptoms of a blood ...
Cancers Free Full-Text Advances in Biomarker-Driven Targeted ...
WebOn this page about Tafinlar you will find information relating to side effects, age restrictions, food interactions, whether the medicine is available at a government subsidised price on the pharmaceutical benefits scheme (PBS) as well as other useful information. WebDabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.. The most common side effects include papilloma (warts), … optic disc swelling in children
What are the possible side effects of RADICAVA?
WebDec 17, 2024 · The NCI-sponsored clinical trial, called DREAMseq, included people with metastatic melanoma whose tumors had a specific mutation in the BRAF gene, called V600. It tested initially giving patients a combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) or a combination of the targeted therapies dabrafenib … WebV600E/K mutation-positive cutaneous melanoma. Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) as indicated in the SmPC and by prescription, that has been started before inclusion of the patient into the study; ≥ 18 years of age. Written informed consent signed. WebFor other skin toxicities, withhold TAFINLAR and/or MEKINIST for intolerable or severe skin toxicity. Resume TAFINLAR and/or MEKINIST at a lower dose in patients with improvement or recovery from skin toxicity within 3 weeks. Permanently discontinue TAFINLAR and/or MEKINIST if skin toxicity has not improved within 3 weeks. Hyperglycemia. optic disk function